教員・教室員について

  1. TOP
  2. 教員・教室員について
  3. 教員・教室員紹介
  4. 教員
  5. 第一内科
  6. 土橋 賢司（つちはし けんじ）

助教

名前 土橋 賢司（つちはし けんじ）
卒業年 2008(平成20)年
学位取得年月 2016年10月 医学博士学位取得
専門領域 腫瘍内科学、腫瘍生物学
資格 日本内科学会認定医・総合内科専門医
日本臨床腫瘍学会がん薬物療法専門医・指導医
日本消化器病学会専門医
所属学会 日本臨床腫瘍学会　日本内科学会　 日本癌治療学会
日本消化器病学会　 日本癌学会　日本サルコーマ治療研究学会
日本小児血液・がん学会　レックリングハウゼン病学会
米国癌学会（AACR）　欧州臨床腫瘍学会(ESMO)
WJOG消化器グループ（若手会FLAG副代表）
JCOG食道がんグループ
JCOG骨軟部腫瘍グループ
JCCG横紋筋肉腫委員会(JRSG) 成人ワーキンググループ

略歴

2008-2010年 聖路加国際病院 初期臨床研修医
2010-2011年 九州大学病院 血液・腫瘍内科 医員
2011-2015年9月 慶應義塾大学医学部 先端医科学研究所遺伝子制御研究部門（佐谷秀行教授） 研究員
2015年10月-2016年3月 九州大学病院 血液・腫瘍内科 医員 （外来化学療法室担当）
2016年4月 九州大学病院 遺伝子細胞療法部 医員
2017年4月 九州大学病院 血液・腫瘍・心血管内科 臨床助教
2017年8月 同上 助教
2022年8月

希少がんセンター内科系コーディネーター併任
現在に至る

代表的業績

  1. Yae T, Tsuchihashi K, et al. Alternative splicing of CD44 mRNA by ESRP1 enhances lung colonization of metastatic cancer cells. Nature Communications. 2012;3: 833.
  2. Tsuchihashi K, et al. Systemic chemotherapy for non-mucinous appendiceal adenocarcinoma: a case report and literature review. International Cancer Conference Journal, 2013;2: 36-40.
  3. Yoshikawa M, Tsuchihashi K, et al. xCT inhibition depletes CD44v-expressing tumor cells that are resistant EGFR-targeted therapy in head and neck squamous cell carcinoma. Cancer Research, 2013;71:1855-66.
  4. Seishima R, et al. Ink4a/Arf-dependent Loss of Parietal Cells Induced by Oxidative Stress Promotes CD44-dependent Gastric Tumorigenesis.
    Cancer Prevention Research, 2015;8;492-501.
  5. Wang M, et al. CD44-variant positive population in head and neck tumors through controlled intracellular navigation of cisplatin-loaded nanomedicines. J Control Release. 2016;230:26-33.
  6. Tsuchihashi K, et al. The EGF receptor promotes the malignant potential of glioma by regulating amino acid Transport system xc(-).
    Cancer Research. 2016;76:2954-63
  7. Tsuchihashi K, et al. Programmed death-ligand 1 expression associates with fibrosarcomatous transformation of dermatofibrosarcoma protuberans. Mol Clin Oncol, 2017;6:665-668
  8. Tsuchihashi K, et al. Regorafenib-induced retinal and gastrointestinal hemorrhage in a metastatic colorectal cancer patient with liver dysfunction: a case report. Medicine (Baltimore) 2017;96:e8285.
  9. Tsuchihashi K, et al. Metastatic esophageal cancer presenting as shock by injury of vagus nerve mimicking baroreceptor reflex: A case report. Medicine (Baltimore) 2017;96:e8987.
  10. Tsuchihashi K, et al. Role of Predictive Value of the Modified Glasgow Prognostic Score for Later-line Chemotherapy in Patients With Metastatic Colorectal Cancer.Clin Colorectal Cancer 2018;17:e687-e689
  11. Suina K and Tsuchihashi K (equally contributed), et al. Epidermal growth factor receptor promotes glioma progression by regulating xCT and GluN2B-containing N-methyl-d-aspartate-sensitive glutamate receptor signaling. Cancer Sci 2018;109:3874-3882 
  12. Tsuchihashi K, et al. Metastatic esophageal carcinosarcoma comprising neuroendocrine carcinoma, squamous cell carcinoma, and sarcoma: A case report. Medicine (Baltimore) 2018;97: e12796
  13. Nio K, Tsuchihashi K, et al. Exploratory retrospective study of risk factors for thromboembolism treated with multi-kinase inhibitor pazopanib or Lenvatinib. International Journal of Surgery Oncology. 2020;5:e89.
  14. Taguchi R, Tsuchihashi K, et al. Thrombocytopenia caused by dexamethasone in a patient with colorectal cancer. Internal Medicine 2020;59:2571-2575.
  15. Tsuruta N, Tsuchihashi K, et al. RNA N6-methyladenosine demethylase FTO regulates PD-L1 expression in colon cancer cells. Biochem Biophys Res Commun. 2020;530:235-239.
  16. Tsuchihashi K, et al. Eribulin as a first-line treatment for soft tissue sarcoma patients with contraindications for doxorubicin. Sci Rep. 2020;10:20896.
  17. Tsuchihashi K, et al. Spontaneous Regression of Metachronous Intra-Abdominal Desmoid Tumor in a Patient with Familial Adenomatous Polyposis. Case Rep Oncol 2022;15:71–77
  18. Tsuchihashi K, Hirata Y (equally contributed), et al.  Presence of spontaneous epithelial-mesenchymal plasticity in esophageal cancer. Biochem Biophys Rep. 2022;30:101246.
  19. Tsuchihashi K, et al. Survival outcomes including salvage therapy of adult head and neck para-meningeal rhabdomyosarcoma: a multicenter retrospective study from Japan. BMC Cancer.2023;23(1):1046.
  20. Tsuchihashi K and Baba E.Epithelioid Hemangioendothelioma -Its history, clinical features, molecular biology and current therapy. Jpn J Clin Oncol. 2024;54(7):739-747
  21. Okuma HS, Watanabe K, Tsuchihashi K, et al.Phase II Trial of Nivolumab in Metastatic Rare Cancer with dMMR or MSI-H and Relation with Immune Phenotypic Analysis (the ROCK Trial)
    Clin Cancer Res. 2023;29(24):5079-5086.
  22. Tsuchihashi K, et al.Therapeutic use of granulocyte colony-stimulating factor (G-CSF) in patients with febrile neutropenia: a comprehensive systematic review for clinical practice guidelines for the use of G-CSF 2022 from the Japan Society of Clinical Oncology
    Int J Clin Oncol. 2024;29(6):700-705
  23. Matsumura T, Tsuchihashi K, et al. Lymphoproliferative Disorder in an Esophageal Cancer Patient Treated with Pembrolizumab. Intern Med 2025;64(11):1728-1732
  24. Takigawa A, Tsuchihashi K, et al.  Clinical outcomes and genomic alterations in patients with metastatic malignant phyllodes tumors. Jpn J Clin Oncol. 2026;56(2):139-147
  25. Okuma HS, Tsuchihashi K, et al. Real-world characterization of patients with advanced or metastatic liposarcoma, including dedifferentiated liposarcoma, in Japan in the MASTER KEY project. 2026 https://doi.org/10.1093/jjco/hyag004

一覧